The Efficacy of Silymarin in Decreasing Transaminase Activities in Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial

Ali Hajaghamohammadi; Amir Ziaee; Ramin Rafiei

Hepatitis Monthly

Official Journal of Research Center for Gastroenterology and Liver Diseases

Current Issue All Issues In Press Articles Search Accepted Manuscripts

Journal Information Boards and committees Indexing and Listing Sources Journal Metrics Publication Ethics and Malpractice Statement Reviewer and AE Registration Form Support Contact Us Open Peer Review (OPR)

APC

Authors Guide Submit Manuscript

The Efficacy of Silymarin in Decreasing Transaminase Activities in Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial

Author(s):

Ali Akbar Hajaghamohammadi¹,

Amir Ziaee^2,*,

Ramin Rafiei¹

1Metabolic Disease Research Center, Qazvin University of Medical Sciences, Qazvin, IR.Iran

2Metabolic Disease Research Center, Qazvin University of Medical Sciences, [email protected], Qazvin, IR.Iran

Hepatitis Monthly:Vol. 8, issue 3; 191-195

Published online:Sep 30, 2008

Article type:Research Article

Received:May 04, 2008

Accepted:Aug 18, 2008

How to Cite:Hajaghamohammadi A A, Ziaee A, Rafiei R. The Efficacy of Silymarin in Decreasing Transaminase Activities in Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial.Hepat Mon.2008;8(3):191-195.

Abstract

Background and Aims: Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of increased liver enzymes. According to statistical reports, 20%-40% of Western population and 5%-30% of the population of Pacific and Asian countries are afflicted with this disease. The prevalence of NAFLD is higher in hyperlipidemic, diabetic and obese people. Considering the high prevalence of NAFLD and its complications and lack of consensus on its treatment, we were motivated to study the efficacy of silymarin on this disease.

Methods: In this randomized clinical trial, 50 patients including 32 men (64%) and 18 women (36%) were divided into case and control groups. The mean age of case group was 40.3 and for control group was 39.9 years. All patients had elevated liver enzymes and had increased liver echogenicity (lipid accumulation) on sonography. The case group was treated with one tablet containing 140 mg silymarin per day for two months and the control group was treated in the same manner with placebo. Before and after the study, weight, body mass index (BMI) and liver transaminases levels were measured for each patient.

Results: The difference between the mean weight and BMI measured before and after the study was not statistically significant in both case and control groups. But the mean ALT and AST levels deceased from 103.1 to 41.4 and 53.7 to 29.1 IU/mL, respectively in case group which was statistically significant (P<0.001 & P<0.001). In the control group, the decrease in mean ALT and AST, with decrease of 7.8 and 2.2 IU/mL, respectively, was not statistically significant.

Conclusions: Considering the significant drop in liver enzymes following administration of silymarin, it seems that after conducting similar studies in order to determine the appropriate doses and treatment periods, this cheap and easy to access drug can be prescribed for treatment of NAFLD.

Keywords

Non-alcoholic Fatty Liver Disease

Non-Alcoholic Steatohepatitis

Silymarin

Full Text

Full text is available in PDF

Import into EndNote Import into BibTex

Share on

Comments

Number of Comments:0

Metrics

Purchasing Reprints

Copyright Clearance Center (CCC) handles bulk orders for article reprints for Brieflands. To place an order for reprints, please click here ( https://www.copyright.com/landing/reprintsinquiryform/ ). Clicking this link will bring you to a CCC request form where you can provide the details of your order. Once complete, please click the ‘Submit Request’ button and CCC’s Reprints Services team will generate a quote for your review.

Search Relations

Author(s):

Ali Hajaghamohammadi:[PubMed][Scholar]
Amir Ziaee:[PubMed][Scholar]
Ramin Rafiei:[PubMed][Scholar]